<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676130</url>
  </required_header>
  <id_info>
    <org_study_id>2007P000414</org_study_id>
    <secondary_id>F8349839</secondary_id>
    <nct_id>NCT00676130</nct_id>
  </id_info>
  <brief_title>Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients</brief_title>
  <official_title>Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Placebo Added to Standard Treatment of Uncomplicated Cellulitis in Emergency Department Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to quantify the effectiveness of Bactrim as additional
      therapy for the treatment of uncomplicated cellulitis in adults, by comparing: standard
      therapy plus Bactrim, versus standard therapy plus placebo.

      The primary hypothesis of this study is that, in light of increasing CA-MRSA prevalence,
      subjects treated with standard therapy plus Bactrim will have higher cure rates than those
      treated with standard therapy plus placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Efficacy</measure>
    <time_frame>12 +/- 2 days; 30 +/- 2 days</time_frame>
    <description>Proportion of subjects in each arm with successful treatment.
Treatment success was assessed by physician examination at 12 +/- 2 days. Non-success was defined as subsequent hospitalization, change in antibiotics, surgical or needle drainage of an abscess, or recurrence of infection within 30 days. Cure was defined as resolution of all symptoms other than mild residual erythema or edema. We confirmed the determination of cure by telephone interview and medical record review at 30 +/- 2 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression to Abscess</measure>
    <time_frame>12 +/- 2 days, 30 days +/- 2 days</time_frame>
    <description>Proportion of subjects in each arm with progression from cellulitis to abscess.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Cellulitis</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cephalexin plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard plus anti-CA-MRSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cephalexin plus trimethoprim-sulfamethoxazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimethoprim-sulfamethoxazole</intervention_name>
    <description>Weight-based dosing in capsule or suspension form according to the following scale:
15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily
20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily
25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily
29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily
60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily
60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily
&gt; 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily</description>
    <arm_group_label>Standard plus anti-CA-MRSA</arm_group_label>
    <other_name>Bactrim</other_name>
    <other_name>Co-trimoxazole</other_name>
    <other_name>Septra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin</intervention_name>
    <description>Weight-based dosing in capsule or suspension form according to the following scale:
15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily
20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily
25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily
29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily
60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily
&gt; 80 kg (176 lbs): Cephalexin 1000 mg four times daily</description>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_label>Standard plus anti-CA-MRSA</arm_group_label>
    <other_name>Keflex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Must have cellulitis as defined here:

               1. Definition A (preferred definition):

                  Recent onset of soft tissue erythema, considered by the treating clinician to be
                  bacterial in origin, and associated with signs of infection that include at least
                  two of the following: pain, swelling, warmth, fever, lymphangitis, induration, or
                  ulceration.

               2. Definition B (ONLY for darkly-pigmented subjects who cannot use Definition A):

                  Recent onset of soft tissue color change, pain, or swelling, considered by the
                  treating clinician to be bacterial in origin, and at least one of the following:
                  warmth, fever, induration, or ulceration

          -  Clinical (non-research) attending physician agrees with treatment with cephalexin
             until 3 days after all symptoms gone, using our weight-based dosing

          -  Responsible clinical attending physician comfortable with adding
             trimethoprim-sulfamethoxazole vs. placebo to the above

          -  Subject understands the study and signs written informed consent.

          -  Subject agrees to drink at least 1 liter of fluid per day.

          -  Subject will commit to all follow-up appointments

        Exclusion Criteria:

          -  Age &lt; 12 months or weight &lt;15 kg

          -  Current skin infection has already been treated

          -  Allergy to sulfa drugs

          -  History of severe allergic reaction to penicillin (defined as anaphylactoid reaction,
             angioedema, bronchospasm)

          -  Current use of any antibiotic (other than topicals)

          -  Diabetes mellitus

          -  Cellulitis complicated by underlying peripheral vascular disease

          -  Renal insufficiency, defined as patient report, clinical suspicion, or creatinine&gt;1.3
             or EGFR&lt;60 on the last-available set of chemistry results in our computer system

          -  Hospital admission required

          -  Presence of &gt; 1 cc of purulent discharge at any time

          -  Cellulitis involving an indwelling vascular, enteric, or urinary catheter

          -  Immunocompromise of any etiology

          -  Pregnancy

          -  Breast feeding

          -  Facial cellulitis (infection is above the clavicles)

          -  Cellulitis associated with marine or freshwater injury, or animal or human bite.
             (Insect bites not excluded.)

          -  History of glucose-6-phosphate dehydrogenase deficiency

          -  Taking coumadin (warfarin), methotrexate, cisapride, phenytoin (dilantin), digoxin, or
             dofetilide

          -  Known megaloblastic anemia due to folate deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J. Pallin, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <results_first_submitted>July 3, 2012</results_first_submitted>
  <results_first_submitted_qc>August 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2012</results_first_posted>
  <last_update_submitted>August 12, 2012</last_update_submitted>
  <last_update_submitted_qc>August 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Daniel Jay Pallin, MD, MPH</investigator_full_name>
    <investigator_title>Associate Research Director, Department of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Cellulitis</keyword>
  <keyword>Bactrim</keyword>
  <keyword>Trimethoprim Sulfamethoxazole</keyword>
  <keyword>MRSA</keyword>
  <keyword>Methicillin-resistant Staphylococcus aureus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Cellulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We enrolled generally-healthy subjects with uncomplicated acute cellulitis from 6/2007 to 12/2011. Eligible subjects were adults and children presenting to EDs of 3 teaching hospitals in Boston, MA.</recruitment_details>
      <pre_assignment_details>Each subject was assigned randomly to a treatment group by the institutions’ research pharmacies. The research pharmacies had no knowledge of subjects’ clinical characteristics. Treating (non-research) clinicians, research clinicians, coordinators, and subjects had no knowledge of the randomization sequence.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Trimethoprim-sulfamethoxazole</title>
          <description>Cephalexin plus trimethoprim-sulfamethoxazole</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Cephalexin plus placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Found ineligible</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trimethoprim-sulfamethoxazole</title>
          <description>Cephalexin plus trimethoprim-sulfamethoxazole</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Cephalexin plus placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.03" spread="15.07"/>
                    <measurement group_id="B2" value="32.43" spread="15.15"/>
                    <measurement group_id="B3" value="34.71" spread="15.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Efficacy</title>
        <description>Proportion of subjects in each arm with successful treatment.
Treatment success was assessed by physician examination at 12 +/- 2 days. Non-success was defined as subsequent hospitalization, change in antibiotics, surgical or needle drainage of an abscess, or recurrence of infection within 30 days. Cure was defined as resolution of all symptoms other than mild residual erythema or edema. We confirmed the determination of cure by telephone interview and medical record review at 30 +/- 2 days.</description>
        <time_frame>12 +/- 2 days; 30 +/- 2 days</time_frame>
        <population>Of the 153 randomized subjects, 4 were randomized in error and did not receive study drug, 1 received two doses before it was discovered that he was ineligible, 1 was lost to follow up, and 1 withdrew voluntarily in the first few days after enrollment. This left 146 subjects for intent-to-treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-sulfamethoxazole</title>
            <description>Cephalexin plus trimethoprim-sulfamethoxazole</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cephalexin plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Efficacy</title>
          <description>Proportion of subjects in each arm with successful treatment.
Treatment success was assessed by physician examination at 12 +/- 2 days. Non-success was defined as subsequent hospitalization, change in antibiotics, surgical or needle drainage of an abscess, or recurrence of infection within 30 days. Cure was defined as resolution of all symptoms other than mild residual erythema or edema. We confirmed the determination of cure by telephone interview and medical record review at 30 +/- 2 days.</description>
          <population>Of the 153 randomized subjects, 4 were randomized in error and did not receive study drug, 1 received two doses before it was discovered that he was ineligible, 1 was lost to follow up, and 1 withdrew voluntarily in the first few days after enrollment. This left 146 subjects for intent-to-treat analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was powered to detect a difference in cure rate of 98% in the intervention group vs. 85% in the control group, with 2-sided alpha 0.05. This would yield a number needed to treat of 7.7 for intervention vs. control, and required 144 subjects to achieve 80% power. No data were analyzed until study completion.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression to Abscess</title>
        <description>Proportion of subjects in each arm with progression from cellulitis to abscess.</description>
        <time_frame>12 +/- 2 days, 30 days +/- 2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-sulfamethoxazole</title>
            <description>Cephalexin plus trimethoprim-sulfamethoxazole</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cephalexin plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Progression to Abscess</title>
          <description>Proportion of subjects in each arm with progression from cellulitis to abscess.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We assessed the rate of progression to abscess in the two groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days, assessed via telephone contact, in-person visit, and medical record review.</time_frame>
      <desc>Serious adverse events were considered to be those resulting in hospital admission.</desc>
      <group_list>
        <group group_id="E1">
          <title>Trimethoprim-sulfamethoxazole</title>
          <description>Cephalexin plus trimethoprim-sulfamethoxazole</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Cephalexin plus placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel J. Pallin, MD, MPH</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-525-6614</phone>
      <email>dpallin@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

